Comparison

Almotriptan (malate) European Partner

Item no. HY-B0383-25mg
Manufacturer MedChem Express
CASRN 181183-52-8
Amount 25 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 99.53
Citations [1]Bou J , et al. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol, 2000. 410(1): p. 33-41.|[2]Gras J, et al. Safety profile of almotriptan, a new antimigraine agent. Effects on central nervous system, renal function and respiratory dynamics. Arzneimittelforschung, 2001. 51(9): p. 726-32.
Smiles O=C(O)C(O)CC(O)=O.O=S(CC1=CC2=C(NC=C2CCN(C)C)C=C1)(N3CCCC3)=O
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias PNU180638
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
Neuroscience-Neuromodulation
Manufacturer - Targets
5-HT Receptor
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Molecular Weight
469.55174
Product Description
Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine.IC50:Target: 5-hydroxytryptamine1B/1D (5-HT1B/1D) ReceptorAlmotriptan Malate is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, used for the treatment of Migraine attacks in adults. Almotriptan showed low nanomolar affinity for the 5-HT(1B) and 5-HT(1D) receptors in several species, including the human, while affinity for 5-HT receptors other than 5-HT(1B/1D) was clearly less. Almotriptan did not exhibit significant affinity for several non-5-HT receptors studied up to 100 microM. Almotriptan inhibited forskolin-stimulated cyclic AMP accumulation in HeLa cells transfected with 5-HT(1B) or 5-HT(1D) human receptors [1]. Almotriptan had a mild antiemetic effect and a slight, transient diuretic effect in dogs, although the latter effect is probably of no clinical relevance. In addition, no effect on the respiratory system of conscious guinea pigs was observed following almotriptan treatment. These results indicate that almotriptan has a favourable safety profile with respect to the central nervous, renal and respiratory systems [2].
Manufacturer - Research Area
Neurological Disease
Solubility
DMSO: 100 mg/mL (ultrasonic)|H2O: 33.33 mg/mL (ultrasonic)
Manufacturer - Pathway
GPCR/G Protein; Neuronal Signaling
Isoform
5-HT1 Receptor; mLAG-3
Clinical information
Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close